Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02233751 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

A Phase 1 study, sponsored by Antares Pharma.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target

NCT02233751: Completed Phase 1 study, sponsored by Antares Pharma.

NCT02233751 is a Phase 1 study that has completed, run by Antares Pharma. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02233751, a Phase 1 study, has completed, sponsored by Antares Pharma.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target

Study Summary

Evaluation of pharmacokinetics of subcutaneous testosterone enanthate

Primary Outcome

Cmax = Maximum blood concentration (ng/dL) of TT=Total Testosterone and TE=Testosterone Enanthate

Interventions

  • COMBINATION_PRODUCT Testosterone enanthate auto-injector

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2014-09
Est. Completion 2014-10
Phase Phase 1
Antares Pharma

9 total trials

What the finished NCT02233751 record still lists

NCT02233751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).

The record links to 0 conditions, and to 1 intervention - of which Testosterone enanthate auto-injector is the first listed.

NCT02233751 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02233751 about?

NCT02233751 is a clinical study titled "Pharmacokinetic Study of Subcutaneous Testosterone Enanthate". Evaluation of pharmacokinetics of subcutaneous testosterone enanthate

What is the current status of trial NCT02233751?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-09. Estimated completion is 2014-10.

What interventions are being tested in trial NCT02233751?

The interventions under investigation include: Testosterone enanthate auto-injector (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT02233751?

This trial is sponsored by Antares Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02233751's enrollment target sits among peer trials

12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02233751, the US trial registry maintained by the National Library of Medicine. NCT02233751 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.